Skip to content
buyWeak

Nicole Murphy bought $585 of BIIB

Head of Pharm Ops and Tech at BIOGEN INC.. 3 shares at an average of $195.04, traded Feb 12, 2026, filed Feb 17, 2026.

Conviction score
10
Value
$585
3 shares
Holdings after
19,611
+0% from before
From 52-week low
+72%
low $113.38, close $195.50
From 52-week high
-3%
high $201.18, as of Feb 12, 2026

Score components

  • Role
    Officer
    +15
  • Trade size
    $585 at market
    0
  • Relative to holdings
    Under 1% of holdings (0.0%)
    -5
  • Price context
    Near the top of the 52-week range
    0
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -6.2%, 3m -2.6%, 6m +8.7%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

BIIBOct 13, 2026 · close 228.90
Since filing Feb 17, 2026: +17.0%SPY +14.8% · excess +2.2%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000875045-26-000033, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 12, 2026POpen-market purchase
Common Stock
+3$195.04$58519,611Feb 17, 2026
Feb 13, 2026AGrant or award
Restricted Stock Unitderivative
+10,560$0.00$010,560Feb 17, 2026

Related signals

Other insiders at BIOGEN INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
18Weak
BIIBsell10b5-1
BIOGEN INC.
Lloyd Minor
director
$240k
1,186 shares
-31%
3Weak
BIIBsell10b5-1
BIOGEN INC.
Priya Singhal
Head of Development
$532k
2,660 shares
-25%
0Weak
BIIBsell10b5-1
BIOGEN INC.
Priya Singhal
Head of Development
$134k
748 shares
-11%
0Weak
BIIBsell10b5-1
BIOGEN INC.
Priya Singhal
Head of Development
$69k
517 shares
-8%
19Weak
BIIBsell10b5-1
BIOGEN INC.
Rachid Izzar
Head of Global Product Strat.
$300k
2,223 shares
-26%
23Weak
BIIBsell10b5-1
BIOGEN INC.
Priya Singhal
Head of Development
$481k
3,806 shares
-41%
44Moderate
BIIBbuy
BIOGEN INC.
Caroline Dorsa
director
$152k
1,235 shares
+5%
30Weak
BIIBsell10b5-1
BIOGEN INC.
Stephen A Sherwin
director
$1.3M
8,760 shares
-44%
0Weak
BIIBsell10b5-1
BIOGEN INC.
Priya Singhal
Head of Development
$17k
110 shares
-2%
0Weak
BIIBsell10b5-1
BIOGEN INC.
Priya Singhal
Head of Development
$88k
431 shares
-7%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.